outperform price
thesi updat thing hum waltham massachusett
china yet biopharma dd increment
back capit flow sort deploy
possibl life good us major driver remain
favor comp get tough dont see growth
dip mayb key mental
threshold neg could point would academ
demand europ isnt major surpris potenti
challeng gatan acquisit wherebi uk may play spoiler
despit gener inconsequenti market put gatan
asid firepow remain materi typic
posit share given well north decad valu creativ
transact furthermor realiti thermo
longer cheap longer controversi one best
mega-cap compound market say someth
particularli given fall within challeng healthcar sub-sector
see ytd under-perform vs mean us probabl
belong portfolio fashion growth valu
core reiter outperform go buy today weak share
like keep grind higher
rais revenu mm midpoint
mm improv organ outlook strong
perform mm brammer close
maintain expect mm fx hw
improv outlook china mid-teen begin
yr could strong mid-teen high-teen
rais midpoint
click continu
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
interest mm lower prior guid
mm mm higher prior guid
rais ep midpoint
strong brammer wors fx fx expect hw
still expect dilut ap divestitur
phase across remain mo similar last month
capital-expenditure mm mm vs prior guid facil expans brammer
off-set strong cash flow perf
mm share vs prior guid
biopharma dd
 lsd led china good growth america partial off-set mute eu
dx healthcar msd led clinic dx immunodx
power weaker flu season
industri hsd strength across analyt instrument
 america msd
europ msd
eu actual good end market weaker
germani mute releas fund side
expect impact weak brexit
apac dd
china
everyth growth biopharma continu drive region growth
improv outlook china possibl
brammer expect close
capac shortag cell/gen therapi lead attract price includ reserv fee unus capac
signific margin expans opportun lead accret margin vs slightli dilut
continu build capac lead even better econom gain scale
work eu get final decis gatan end
expand capac brammer steril fill finish biolog manufactur facil
see biolog manufactur busi go msd-to-hsd busi solid hsd grow busi time
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
laboratori corp america
articl articl
time dissemin april
analyst luke sergott jon bristow ross muken primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view research report
